Sp919

MANAGEMENT OF INCIDENTALLY DETECTED GASTRODUODENAL NEUROENDOCRINE TUMORS

Date
May 8, 2023
Explore related products in the following collection:

Society: AGA

This session is co-sponsored by the North American Neuroendocrine Tumor Society (NANETS). Clinically focused session focused on management of incidentally discovered neuroendocrine tumors, with a specific focus on the role of the gastroenterologist in this management. The session will have talks focused on incidentally discovered neuroendocrine tumors including gastroduodenal neuroendocrine tumors, pancreatic neuroendocrine tumors, and colorectal neuroendocrine tumors. Incidental identification of gastroenteropancreatic neuroendocrine tumors is becoming increasing common in gastroenterology practice, and therefore gastroenterologists need to understand how to manage these tumors when they are encountered.

Presenter

Speaker Image for Shria Kumar
University of Miami

Tracks

Related Products

Thumbnail for PLACEHOLDER
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Thumbnail for INTRODUCTION
INTRODUCTION
SOCIETY: AGA
Thumbnail for ACTIVATING TRANSCRIPTION FACTOR 6 ACCELERATES MICROBIOTA-DEPENDENT RISK FOR COLITIS-ASSOCIATED CANCER IN INFLAMMATORY BOWEL DISEASES
ACTIVATING TRANSCRIPTION FACTOR 6 ACCELERATES MICROBIOTA-DEPENDENT RISK FOR COLITIS-ASSOCIATED CANCER IN INFLAMMATORY BOWEL DISEASES
BACKGROUND AND AIMS: Chemoresistance is a major cause of colorectal cancer (CRC) recurrence and death. The critical role of gut microbiome in the efficacy of CRC chemotherapy remains unclear…